Down regulation of soluble guanylate cyclase contributes to bronchial hyperreactivity in asthma

Davina Simoes, Cristina Gratziou, Georgina Xanthou, Charis Roussos, Andreas Papapetropoulos

Research output: Contribution to journalArticle

Abstract

We have used an ovalbumin (OVA) model of inflammatory airway disease to explore the role of soluble guanylyl cyclase (sGC) in bronchial hyperactivity (BHR) and inflammation associated with asthma. OVA treated mice exhibited a 60-80 % reduction in steady-state mRNA levels of sGC subunits compared to control mice as determined by real-time PCR. Similarly, protein levels of the sGC subunits were reduced by 50-70% in animals with asthma. In addition, inhibition of sGC activity using the selective inhibitor 1H-[1,2,4] oxydiazolo[4,3-ea]quinoxalin-1-one (ODQ) lead to increased basal bronchial tone and airway reactivity to methacholine. ODQ-treated mice, also exhibited a significant increase in macrophage number in the bronchiolar lavage (BAL) that was not accompanied by changes in lung histology and interleukin-13 production. These data indicate that sGC inhibition is accompanied by an inflammatory response that is qualitatively different from that observed in asthma (eosinophil infiltration and increased IL-13 production). We conclude that sGC inhibition contributes to the BHR seen in asthma.

Original languageEnglish (US)
Pages (from-to)95-96
Number of pages2
JournalEpitheorese Klinikes Farmakologias kai Farmakokinetikes
Volume23
Issue number1
StatePublished - Mar 18 2005
Externally publishedYes

Fingerprint

Bronchial Hyperreactivity
Down-Regulation
Asthma
Interleukin-13
Ovalbumin
Quinoxalines
Methacholine Chloride
Therapeutic Irrigation
Eosinophils
Soluble Guanylyl Cyclase
Real-Time Polymerase Chain Reaction
Histology
Macrophages
Inflammation
Lung
Messenger RNA
Proteins

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Down regulation of soluble guanylate cyclase contributes to bronchial hyperreactivity in asthma. / Simoes, Davina; Gratziou, Cristina; Xanthou, Georgina; Roussos, Charis; Papapetropoulos, Andreas.

In: Epitheorese Klinikes Farmakologias kai Farmakokinetikes, Vol. 23, No. 1, 18.03.2005, p. 95-96.

Research output: Contribution to journalArticle

Simoes, Davina ; Gratziou, Cristina ; Xanthou, Georgina ; Roussos, Charis ; Papapetropoulos, Andreas. / Down regulation of soluble guanylate cyclase contributes to bronchial hyperreactivity in asthma. In: Epitheorese Klinikes Farmakologias kai Farmakokinetikes. 2005 ; Vol. 23, No. 1. pp. 95-96.
@article{98949d82c9b44fbda8e42573aba1cede,
title = "Down regulation of soluble guanylate cyclase contributes to bronchial hyperreactivity in asthma",
abstract = "We have used an ovalbumin (OVA) model of inflammatory airway disease to explore the role of soluble guanylyl cyclase (sGC) in bronchial hyperactivity (BHR) and inflammation associated with asthma. OVA treated mice exhibited a 60-80 {\%} reduction in steady-state mRNA levels of sGC subunits compared to control mice as determined by real-time PCR. Similarly, protein levels of the sGC subunits were reduced by 50-70{\%} in animals with asthma. In addition, inhibition of sGC activity using the selective inhibitor 1H-[1,2,4] oxydiazolo[4,3-ea]quinoxalin-1-one (ODQ) lead to increased basal bronchial tone and airway reactivity to methacholine. ODQ-treated mice, also exhibited a significant increase in macrophage number in the bronchiolar lavage (BAL) that was not accompanied by changes in lung histology and interleukin-13 production. These data indicate that sGC inhibition is accompanied by an inflammatory response that is qualitatively different from that observed in asthma (eosinophil infiltration and increased IL-13 production). We conclude that sGC inhibition contributes to the BHR seen in asthma.",
author = "Davina Simoes and Cristina Gratziou and Georgina Xanthou and Charis Roussos and Andreas Papapetropoulos",
year = "2005",
month = "3",
day = "18",
language = "English (US)",
volume = "23",
pages = "95--96",
journal = "Epitheorese Klinikes Farmakologias kai Farmakokinetikes",
issn = "1011-6575",
publisher = "PHARMAKON-Press",
number = "1",

}

TY - JOUR

T1 - Down regulation of soluble guanylate cyclase contributes to bronchial hyperreactivity in asthma

AU - Simoes, Davina

AU - Gratziou, Cristina

AU - Xanthou, Georgina

AU - Roussos, Charis

AU - Papapetropoulos, Andreas

PY - 2005/3/18

Y1 - 2005/3/18

N2 - We have used an ovalbumin (OVA) model of inflammatory airway disease to explore the role of soluble guanylyl cyclase (sGC) in bronchial hyperactivity (BHR) and inflammation associated with asthma. OVA treated mice exhibited a 60-80 % reduction in steady-state mRNA levels of sGC subunits compared to control mice as determined by real-time PCR. Similarly, protein levels of the sGC subunits were reduced by 50-70% in animals with asthma. In addition, inhibition of sGC activity using the selective inhibitor 1H-[1,2,4] oxydiazolo[4,3-ea]quinoxalin-1-one (ODQ) lead to increased basal bronchial tone and airway reactivity to methacholine. ODQ-treated mice, also exhibited a significant increase in macrophage number in the bronchiolar lavage (BAL) that was not accompanied by changes in lung histology and interleukin-13 production. These data indicate that sGC inhibition is accompanied by an inflammatory response that is qualitatively different from that observed in asthma (eosinophil infiltration and increased IL-13 production). We conclude that sGC inhibition contributes to the BHR seen in asthma.

AB - We have used an ovalbumin (OVA) model of inflammatory airway disease to explore the role of soluble guanylyl cyclase (sGC) in bronchial hyperactivity (BHR) and inflammation associated with asthma. OVA treated mice exhibited a 60-80 % reduction in steady-state mRNA levels of sGC subunits compared to control mice as determined by real-time PCR. Similarly, protein levels of the sGC subunits were reduced by 50-70% in animals with asthma. In addition, inhibition of sGC activity using the selective inhibitor 1H-[1,2,4] oxydiazolo[4,3-ea]quinoxalin-1-one (ODQ) lead to increased basal bronchial tone and airway reactivity to methacholine. ODQ-treated mice, also exhibited a significant increase in macrophage number in the bronchiolar lavage (BAL) that was not accompanied by changes in lung histology and interleukin-13 production. These data indicate that sGC inhibition is accompanied by an inflammatory response that is qualitatively different from that observed in asthma (eosinophil infiltration and increased IL-13 production). We conclude that sGC inhibition contributes to the BHR seen in asthma.

UR - http://www.scopus.com/inward/record.url?scp=14744290881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744290881&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 95

EP - 96

JO - Epitheorese Klinikes Farmakologias kai Farmakokinetikes

JF - Epitheorese Klinikes Farmakologias kai Farmakokinetikes

SN - 1011-6575

IS - 1

ER -